SGEN - シアトル・ジェネティクス (Seattle Genetics Inc.) シアトル・ジェネティクス



symbol SGEN
会社名 Seattle Genetics Inc (シアトル・ジェネティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 シアトル・ジェネティクス(Seattle Genetics Inc.)は主に癌に対するモノクローナル抗体に基づく治療薬の開発・商品化に従事するバイオテクノロジー会社。同社の候補薬剤であるADCETRIS(brentuximab vedotin)は米国食品医薬品局(FDA)より二つの適応症における承認を受けた。一つは、自家幹細胞移植(ASCT)の障害が発生した後、またはASCT候補者ではない患者に対する二つ以上の前マルチエージェントの化学療法レジメンの障害が発生した後に、ホジキンリンパ腫患者に対する治療である。もう一つは、前マルチエージェントの化学療法レジメンの障害が発生した後に、全身未分化大細胞リンパ腫(ALCL)の患者に対する治療である。ADCETRISは抗体医薬品複合体(ADC)であり、抗CD30モノクローナル抗体により構成され、同社の技術を利用して、微小管破壊剤であるモノメチルアウリスタチンE(MMAE)にプロテアーゼ切断可能なリンカーで接続している。   シアトル・ジェネティクスは、米国のバイオテクノロジ―企業。抗体を使用した癌の治療薬の開発と商品化に従事。同社は抗体が持つ標的化能力を利用し、殺細胞剤を直接がん細胞に届けるようにデザインされた技術抗体薬物複合体(ADC)の開発に特化している。武田薬品工業株式会社と提携し、ADCETRISの共同開発を行う。   Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.
本社所在地 21823 30th Drive SE Bothell WA 98021 USA
代表者氏名 Clay B. Siegall Clay B. Siegall
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 425-527-4000
設立年月日 35612
市場名 NASDAQ National Market System
ipoyear 2001年
従業員数 1100人
EBITDA EBITDA(百万ドル) -173.43500
終値(lastsale) 77.17
時価総額(marketcap) 12253938665.94
時価総額 時価総額(百万ドル) 11401.23
売上高 売上高(百万ドル) 575.65900
企業価値(EV) 企業価値(EV)(百万ドル) 10953.253
当期純利益 当期純利益(百万ドル) -44.62200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Seattle Genetics Inc. revenues increased 43% to $310.8M. Net loss decreased 70% to $35.4M. Revenues reflect Net product sales increase of 51% to $217.8M Collaboration and license agreement reve increase of 31% to $56.7M Royalty revenues increase of 23% to $36.2M. Lower net loss reflects Investment and other income (loss) net increase from $2.2M to $88.7M (income).



   Expert Ratings for Seagen  2022/04/29 20:29:02 Benzinga
Within the last quarter, Seagen (NASDAQ: SGEN ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 5 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 4 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Seagen. The company has an average price target of $166.78 with a high of $200.00 and a low of $136.00. Below is a summary of how these 9 analysts rated Seagen over the past 3 … Full story available on
   Read Why This Analyst Is ''Encouraged'' By Seagen''s Q1 Sales  2022/04/29 19:40:38 Benzinga
Following Seagen Inc''s (NASDAQ: SGEN ) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance. The analysts have raised the price target to $136 from $132, with the Sector Perform rating unchanged. Though the reiteration of the FY guide confirms performance remains on a plan over a year of execution and ramping readouts. Seagen reported
   Seagen Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:SGEN)  2022/04/29 17:38:46 Seeking Alpha
The following slide deck was published by Seagen Inc.
   Seagen Inc. (SGEN) Q1 2022 Earnings Call Transcript  2022/04/29 02:31:04 The Motley Fool
SGEN earnings call for the period ending March 31, 2022.
   Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2022 Results - Earnings Call Transcript  2022/04/28 22:51:09 Seeking Alpha
Seagen Inc. (NASDAQ:NASDAQ:SGEN) Q1 2022 Earnings Conference Call April 28, 2022 04:30 PM ET Company Participants Peggy Pinkston - Senior Vice President of Investor Relations Clay Siegall -…
   Private Advisor Group LLC Has $2.67 Million Position in Seagen Inc. (NASDAQ:SGEN)  2021/12/04 11:00:42 Transcript Daily
Private Advisor Group LLC boosted its stake in shares of Seagen Inc. (NASDAQ:SGEN) by 48.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,738 shares of the biotechnology companys stock after acquiring an additional 5,129 shares during the quarter. Private []
   Insider Selling: Seagen Inc. (NASDAQ:SGEN) Director Sells 301,444 Shares of Stock  2021/12/03 13:28:42 Transcript Daily
Seagen Inc. (NASDAQ:SGEN) Director Bros. Advisors Lp Baker sold 301,444 shares of the firms stock in a transaction that occurred on Tuesday, November 30th. The stock was sold at an average price of $160.33, for a total transaction of $48,330,516.52. The transaction was disclosed in a document filed with the SEC, which is available through []
   Moser Wealth Advisors LLC Increases Holdings in Seagen Inc. (NASDAQ:SGEN)  2021/11/29 13:34:42 Dakota Financial News
Moser Wealth Advisors LLC lifted its position in shares of Seagen Inc. (NASDAQ:SGEN) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,580 shares of the biotechnology companys stock after acquiring an additional 82 shares during the quarter. Seagen accounts for []
   Comerica Bank Lowers Position in Seagen Inc. (NASDAQ:SGEN)  2021/11/28 11:00:45 Dakota Financial News
Comerica Bank cut its holdings in shares of Seagen Inc. (NASDAQ:SGEN) by 3.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,630 shares of the biotechnology companys stock after selling 324 shares during the quarter. Comerica Banks holdings in Seagen were []
   Brokerages Anticipate Seagen Inc. (NASDAQ:SGEN) Will Post Earnings of -$0.74 Per Share  2021/11/27 19:12:41 Transcript Daily
Wall Street brokerages forecast that Seagen Inc. (NASDAQ:SGEN) will report earnings of ($0.74) per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Seagens earnings, with the lowest EPS estimate coming in at ($1.15) and the highest estimate coming in at ($0.28). Seagen reported earnings per share of $0.90 []
   Seagen Inc (SGEN) President & CEO Clay B Siegall Sold $4.8 million of Shares  2021/08/07 17:15:10 GuruFocus
Related Stocks: SGEN ,
   Seagen Inc (SGEN): Price Now Near $160.19; Daily Chart Shows An Uptrend on 100 Day Basis  2021/08/06 15:15:34 ETF Daily News
This is the 2nd day in a row sgen has seen its price head down. The post Seagen Inc (SGEN): Price Now Near $160.19; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .
   numbers crunched for you before earnings results Seagen (NASDAQ:SGEN)  2021/07/29 18:20:00 Stock Market Daily
Earnings results for Seagen , Analyst Opinion on Seagen , Earnings and Valuation of (NASDAQ:SGEN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post numbers crunched for you before earnings results Seagen (NASDAQ:SGEN) appeared first on .
   Global Antibody Production Services Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Roche, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Pfizer, Bayer, Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Biogen, AstraZeneca, Sanofi, Alexion Pharmaceuticals, Seattle Genetics  2021/07/24 01:29:29 Jumbo News
The report on Global Antibody Production Services Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
   EFG Asset Management (Americas) Corp. Buys Generac Holdings Inc, Tradeweb Markets Inc, XPO ...  2021/07/23 16:38:12 GuruFocus
Related Stocks: SGEN , IGF , PFF , VCYT , XNCR , BPMC , GNRC , TW , XPO , REET , INCY , ARGX , IAU , MKTX , VRSK , CVS , FGEN , NOBL ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シアトル・ジェネティクス SGEN Seattle Genetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)